Breaking News

Cangene Obtains Alzheimer’s Technology from UBC

February 22, 2013

Aims to advance an immune therapeutic treatment

Cangene has obtained commercial rights to a new technology targeting Alzheimer's Disease (AD) developed at The University of British Columbia (UBC). Following the successful research collaboration with the inventor, Dr. Neil Cashman at UBC, Cangene aims to advance an immune therapeutic treatment approach by targeting the toxic form of amyloid-beta with the potential to directly impact the disease’s mechanism of action.
 
"We are pleased to have the opportunity to collaborate with Dr. Cashman, who is an expert in misfolded protein diseases and help advance his ground-breaking research in Alzheimer's disease" said Dr. Laura Saward, Cangene's chief scientific officer. "While this work is in its early stages, it is showing promise for the development of a novel immunotherapy to address this devastating disease and fits Cangene's refocused strategy."
 
"This is an all-Canadian solution in terms of its discovery, development and advancement towards the clinic," said Dr. J.P. Heale, associate director of UBC's University-Industry Liaison Office. "The partnerships developed to advance Dr. Cashman 's outstanding research are an excellent example of how Canadian universities, funding agencies and industry partners can work together to tackle a devastating disease of national and global importance."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent